Compare URG & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URG | KMDA |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.8M | 385.3M |
| IPO Year | N/A | N/A |
| Metric | URG | KMDA |
|---|---|---|
| Price | $1.25 | $7.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $2.52 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 9.9M | 102.2K |
| Earning Date | 11-03-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 2.85% |
| EPS Growth | N/A | ★ 30.41 |
| EPS | N/A | ★ 0.35 |
| Revenue | $39,411,000.00 | ★ $174,787,000.00 |
| Revenue This Year | N/A | $14.90 |
| Revenue Next Year | $183.54 | $9.91 |
| P/E Ratio | ★ N/A | $19.76 |
| Revenue Growth | ★ 138.94 | 10.36 |
| 52 Week Low | $0.55 | $5.54 |
| 52 Week High | $2.35 | $9.16 |
| Indicator | URG | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 55.02 |
| Support Level | $1.17 | $6.63 |
| Resistance Level | $1.46 | $7.07 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 27.62 | 70.32 |
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.